Search
Now showing items 1-7 of 7
Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina
(Baishideng Publishing Group Inc, 2018-01-27)
Abstract
Aim: To investigate any changing trends in the etiologies of hepatocellular carcinoma (HCC) in Argentina during the last years.
Methods: A longitudinal cohort study was conducted by 14 regional hospitals ...
Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.
(Baishideng Publishing Group, 2018-01-27)
AIM:
To investigate any changing trends in the etiologies of hepatocellular carcinoma (HCC) in Argentina during the last years.
METHODS:
A longitudinal cohort study was conducted by 14 regional hospitals starting in ...
Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
(Wolters Kluwer Health, Inc., 2016-04-28)
BACKGROUND AND AIM:
The Up-to-7 criteria on the basis of the explanted liver features categorize patients at higher risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). The aim of this study ...
Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort
(Wiley, 2021-04)
Abstract
Background & aim: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) has a poor prognosis, and the adjusted effect of different treatments on post-recurrence survival (PRS) has not been ...
LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study
(Elsevier, 2020-11)
Abstract
Introduction and objectives: The liver imaging reporting data system (LI-RADS) for hepatocellular carcinoma (HCC) was proposed to standardize and enhance consensus of reporting. However, clinical utility of LI-RADS ...
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study
(Wiley, 2021-12)
Abstract
Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best ...
Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
(Baishideng Publishing Group, 2021-06)
Abstract
Although hepatocellular carcinoma is considered a highly lethal malignancy, recent therapeutic advances have been achieved during the last 10 years. This scenario resulted in an unprecedented improvement in ...